Baxter to lead hemodialysis research consortium for German program
Baxter announced receipt of a major research and development grant from the German Federal Ministry of Education and Research program to lead a consortium investigating an anticoagulation-free hemodialysis, or HD, option for end-stage renal disease, or ESRD, patients. The grant provides EUR1.5M in funding over three years to Baxter's research team in Hechingen, Germany, and the consortium partners to find a solution that will improve health-related, quality-of-life outcomes for the millions of patients receiving HD therapy globally. Anticoagulant use is a necessary component of HD that helps prevent blood clotting during therapy sessions, which are typically performed three days a week for an average of four hours per session. HD patients can experience short-term side effects from the anticoagulants, such as increased bleeding time at the end of a dialysis session. The consortium is taking a novel approach to its research by analyzing modifications of dialysis membranes to minimize the interaction between blood and membrane surfaces, which is the main cause of blood clotting.